Plasma Fractionation Market Players:
- CSL Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Kedrion S.p.A
- Octapharma AG
- Bio Products Laboratory Ltd.
- Biotest AG
- LFB Group
- Japan Blood Products Organization
- Intas Pharmaceuticals Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of plasma fractionation is estimated at USD 39.64 Billion.
The global plasma fractionation market size was more than USD 36.95 Billion in 2025 and is anticipated to grow at a CAGR of over 8.1%, reaching USD 80.51 Billion revenue by 2035.
North America plasma fractionation market will hold over 41.6% share by 2035, fueled by a high number of hemophilic patients and rising prevalence of other chronic diseases.
Key players in the market include CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Octapharma AG, Bio Products Laboratory Ltd., Biotest AG, LFB Group, Japan Blood Products Organization, Intas Pharmaceuticals Ltd.
